Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab in early-stage or locally advanced HER2-positive breast cancer
NCT02586025Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2016
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of pertuzumab in HER2-positive breast cancer, sponsored by Roche. Started Mar 2016; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02586025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586025.